Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic.
Javier Martín-BrotoNadia HindiSamuel AguiarRonald Badilla-GonzálezVictor Castro-OlidenMatias ChacónRaquel Correa-GenerosoEnrique de ÁlavaDavide María DonatiMikael ErikssonMartin Falla-JimenezGisela GermanMaria Leticia Gobo SilvaFrancois GouinAlessandro GronchiJuan Carlos Haro-VarasNatalia Jiménez-BrenesBernd KasperCelso Abdon Lopes de MelloRobert MakiPaula Martínez-DelgadoHector Martínez-SaidJorge Luis Martinez-TlahuelJose Manuel Morales-PérezFrancisco Cristobal Muñoz-CasaresSuely A NakagawaEduardo Jose Ortiz-CruzEmanuela PalmeriniShreyaskumar PatelDavid S MouraSilvia StacchiottiMarie Pierre SunyachClaudia M ValverdeFederico WaisbergJean-Yves BlayPublished in: The oncologist (2020)
The Sarcoma European-Latin American Network (SELNET) consensus on sarcoma prioritization care during the COVID-19 era issued 125 pragmatical recommendations distributed as higher or lower priority to protect critical decisions on sarcoma care during the COVID-19 pandemic. A multidisciplinary team from 11 countries reached consensus on 115 recommendations. The consensus was lower among lower-priority recommendations, which shows reticence to postpone actions even in indolent tumors. The European Society for Medical Oncology-Magnitude of Clinical Benefit scale was applied as support for prioritizing systemic treatment. Consensus on 115 of 125 recommendations indicates a high level of convergence among experts. The SELNET consensus provides a practice tool for guidance in the decisions of sarcoma multidisciplinary treatment committees during the COVID-19 outbreak.